HOME > ARCHIVE

ARCHIVE

OPINION

March 13, 2006
Takeda Promoting Basen OD Tables to Win Market Competition

March 13, 2006
JPA Holds 100th Assembly of House of Delegates

March 13, 2006
Norvasc Was Most-prescribed Drug in 2005: IMS Japan

March 13, 2006
MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

March 13, 2006
Bushu Pharm. Starts Up New Lines for Biotech Drugs

March 13, 2006
MEDICAL DEVICE NEWS IN BRIEF

March 13, 2006
REGULATORY NEWS IN BRIEF

March 6, 2006
Bayer, Onyx Initiate PIII Lung Cancer Study Using Nexavar

March 6, 2006
SEMIANAR

March 6, 2006
Switch to Aromasin Maintains QOL of Breast Cancer Patients: IES Study

March 6, 2006
Pfizer Japan to Appoint New President & CEO

March 6, 2006
R&D NEWS IN BRIEF

March 6, 2006
GSK to Participate in Vaccine Business in Japan

March 6, 2006
MEDICAL DEVICE NEWS IN BRIEF

March 6, 2006
MPC, Lequio Pharma License Zione to Yuhan of South Korea

March 6, 2006
47 Chemotherapy Specialists to Be Certified by JSMO in April

March 6, 2006
Chugai Licenses Conditionally Immortalized Cell Line from Cambrex

March 6, 2006
NEW BOOKS

March 6, 2006
Kyowa Hakko Licenses Parkinson's Treatment from Britannia

March 6, 2006

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…